Legal Representation
Attorney
Mark Mutterperl
USPTO Deadlines
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 17, 2018 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Aug 17, 2018 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Feb 23, 2018 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jan 10, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 10, 2018 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jan 10, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 13, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 13, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 11, 2017 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Dec 4, 2017 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 6, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 6, 2017 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 6, 2017 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 23, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 23, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 8, 2017 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Mar 7, 2017 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 3, 2017 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
analgesic preparations; antibiotic preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sunburn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for wounds; topical anesthetics; delivery systems in the nature of topical applications, namely, foams, gels, creams, sprays, lotions and ointments which act as a base and prepare the skin to receive therapeutic preparations that are absorbed into the blood stream through the skin
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of a cannabis leaf between the words BLACK LABEL all displayed inside a rectangular border.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005